BBX (BBX) was upgraded to hold at TheStreet Ratings.
Coca-Cola Enterprises (CCE) was downgraded at Goldman Sachs to neutral from buy. Valuation call, based on a $40 price target, Goldman said.
CEC Entertainment (CEC) was downgraded to hold at TheStreet Ratings.Clean Harbors (CLH) was upgraded at Oppenheimer to outperform from perform. $72 price target. Company is seeing higher end-market demand and has better potential for revenue synergy, Oppenheimer said. eBay (EBAY) was upgraded at Canaccord Genuity to buy from hold. $67 price target. Marketplaces and PayPal can continue to drive growth, Canaccord said. $67 price target. General Mills (GIS) was downgraded at Morgan Stanley to equal-weight from overweight. $49 price target. Company lacks near-term catalysts, Morgan Stanley said. Intel (INTC) was downgraded at JMP Securities to market perform from outperform. Company will no longer pursue the Haswell architecture, JMP Securities said. News Corp. (NWSA) was upgraded at Credit Suisse to outperform from neutral. $36 price target. Company should see higher cable growth and margin expansion, Credit Suisse said. RF Micro (RFMD) was upgraded at Canaccord Genuity to buy from hold. $7 price target. Company can gain share in the LTE smartphone market, Canaccord Genuity said. Regal Entertainment (RGC) was downgraded at MKM Partners to neutral from buy. Company lacks near-term catalysts, MKM said. Valassis (VCI) was downgraded at Lazard Capital Markets to neutral from buy. Valuation call, based on a $36 price target, Lazard Capital Markets said. Yahoo! (YHOO) was downgraded at Pivotal Research Group to hold from buy. Valuation call, based on a $26 price target, Pivotal Research said. STOCK COMMENTS/EPS CHANGES Alexion Pharmaceuticals (ALXN) numbers were cut at UBS. Shares are now seen reaching $120. Estimates were also lowerd on FDA warning letter and EU updates, UBS said. Buy rating. BlackBerry (BBRY) estimates were raised at UBS through 2015. Quarter comforted by margin, lean channel, enterprise prospects, and guidance, UBS said. Neutral rating and $13 price target. Biogen Idec (BIIB) numbers were raised at UBS. Shares are now seen reaching $200. Estimates were also raised on lower risk, BG-12 pricing, UBS said. Neutral rating.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV